

Cambridge University Press

978-0-521-15399-7 - Stahl's Illustrated: Anxiety, Stress, and PTSD

Stephen M. Stahl and Meghan M. Grady and Nancy Muntner

Index

[More information](#)

## Stahl's Illustrated

## Index

- acamprosate, 104, 122–3, 148, 149
- acceptance and commitment therapy (ACT), 135, 139, 147, 153
- accidents, and risk of PTSD, 36
- adherence, to medication by PTSD patients with traumatic brain injury, 167
- adjunctive medications, for PTSD, 104, 148
- adrenal gland, 8
- adrenocorticotrophic hormone (ACTH), 8, 32, 55, 128
- adverse childhood experience, as risk factor for PTSD, 30. *See also* childhood abuse
- Afghanistan war, 157–8
- alcohol abuse: and acamprosate, 122–3, 149; comorbidity of with PTSD, 28, 122, 149; and diazepam, 103; and military populations, 156; and naltrexone, 122–3, 149
- allopregnanolone, 129
- alpha 1 adrenergic receptors: and anxiety, 49; blockade of and side effects of tricyclic antidepressants, 92; and noradrenergic hyperactivation, 47; and trazodone, 106
- alpha 1 antagonists, 104, 108, 149, 152
- alpha 2 delta ligands, 90, 100–1, 152
- alpha 2 receptors, and mirtazapine, 105
- alprazolam, 103
- American Civil War, 24
- amitriptyline, 93
- amnesia, and traumatic brain injury, 162
- AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), 53
- amygdala: and fear response, 3, 5, 6–7, 9, 10, 12, 125, 127; and neuroimaging findings in PTSD, 35; and noradrenergic projections, 46; serotonin transporter genotype and, 42–3; and worry, 3
- anger, as symptom of PTSD, 27
- anterior cingulate cortex (ACC), and emotional aspects of fear, 5
- anticholinergic effects, of paroxetine, 66
- anticonvulsants, 120–1
- antidepressants: and MAOIs, 97; sedating forms of, 105–7. *See also* tricyclic antidepressants
- antipsychotics, and traumatic brain injury, 167. *See also* atypical antipsychotics
- anxiety: definition of, 1, 4; GABA and experience and expression of, 50, 52; and GABA-A receptors, 51; and glutamate, 52; and hippocampus, 11; neuroanatomy of compared to fear, 4; role of amygdala in, 3; and stress inoculation training, 136. *See also* anxiety disorders

- anxiety disorders: and citalopram, 74; comorbidity of with PTSD, 28, 151; COMT and risk of, 58; as defined in DSM-IV-TR, 1; and desvenlafaxine, 82; and diazepam, 103; fear and worry as core symptoms of, 2; and fluoxetine, 70; and lorazepam, 103; and milnacipran, 86; neurobiology of, 15–22; and paroxetine, 66; and presymptomatic state, 16; and risk of cardiovascular issues, 6; and sertraline, 68; and venlafaxine, 80. *See also* anxiety; generalized anxiety disorder
- anxiolytics, noradrenergic mechanisms for novel forms of, 47. *See also* benzodiazepines
- appetite suppressants, and MAOIs, 97
- aripiprazole, 115
- arousal, and relationship between chronic pain and PTSD, 38. *See also* hyperarousal
- asenapine, 119
- assessment, of PTSD: for comorbid disorders and complications, 146; screening tools for, 144. *See also* diagnosis
- asthma, 9
- atypical antipsychotics: as adjuncts, 104, 148; characteristics of specific agents, 112–19; mechanisms of action, 111. *See also* antipsychotics
- atypical depression, and phenelzine, 99
- autism: and aripiprazole, 115; and risperidone, 112
- automatic thoughts, and cognitive restructuring, 134
- autonomic nervous system, and physiology of fear, 6
- avoidance: and diagnostic criteria for PTSD, 26, 27; and relationship between chronic pain and PTSD, 38
- battle fatigue, 24
- behavior, and neurophysiology of fear, 10
- benzodiazepines: clinical characteristics of selected forms, 103; and GABA-A receptors, 51; mechanism of action, 102; second-line forms of, 90, 148; and traumatic brain injury, 167; treatment of PTSD and comorbid anxiety disorder with, 151
- beta blockers, 125
- beta 1 receptors, 47, 49
- bipolar depression: and olanzapine, 113; and quetiapine, 114
- bipolar disorder: and anticonvulsants, 120; and atypical antipsychotics, 111–16
- blood pressure, 6. *See also* hypertension
- borderline personality disorder, and dialectical behavior therapy, 138
- brain-derived neurotrophic factor (BDNF), 31, 34, 63
- buprenorphine, 149
- bupropion, 149, 150
- calcium, and voltage-sensitive ion channels, 54, 100
- cardiac impairment. *See* special populations
- cardiovascular issues, anxiety disorders and risk of, 6
- catechol-O-methyl-transferase (COMT), 57–8
- childhood abuse, as risk factor for PTSD, 30, 31, 34, 36, 37. *See also* adverse childhood experience
- children. *See* adverse childhood experience; infants; special populations
- cholinesterase inhibitors, 168
- chronic pain, comorbidity of with PTSD, 28, 38, 146, 153, 160
- citalopram, 65, 74–5
- Clinician-Administered PTSD Scale (CAPS-2), 144
- clonazepam, 103

- cognitive behavioral therapy, for PTSD: and acceptance and commitment therapy, 139; and anxiety disorders, 151; and chronic pain, 153; and cognitive restructuring, 134; for depression, 150; and dialectical behavior therapy, 138; and exposure therapy, 133; and eye movement desensitization and reprocessing, 137; and motivational interviewing, 142; overview of, 131–2, 135, 140, 147; and seeking safety therapy, 141; and stress inoculation training, 136; and traumatic brain injury, 167
- cognitive impairments: and adherence to medication, 167; and persistent postconcussive syndrome, 163, 168
- cognitive rehabilitation therapy, 168
- cognitive restructuring, 132, 134, 147, 168
- combat, as risk factor for PTSD, 36, 37, 156, 158
- comorbidity, and PTSD: and anxiety disorders, 151; and chronic pain, 28, 38, 146, 153; and depression, 150; and physical illnesses, 146; prevalence of, 28, 146; and sleep problems, 152; and substance abuse, 149
- computerized tomography (CT), and traumatic brain injury, 161
- conditioned fear extinction, 58
- coronary artery disease, 7
- cortico-striatal-thalamic-cortical (CSTC) loops, 14, 52, 55
- corticotrophin releasing factor (CRF), 8, 32, 40
- cortisol, 7, 32, 126
- CRF 1 receptor antagonists, 124, 128
- D-cycloserine, 124, 127
- CYP450 enzymes: and desvenlafaxine, 82; and duloxetine, 84; and fluoxetine, 70; and fluvoxamine, 72; and paroxetine, 66
- Davidson Trauma Scale (DTS), 144
- decongestants, and MAOIs, 97
- depression: and amitriptyline, 93; and aripiprazole, 115; and cognitive behavioral therapy, 150; comorbidity of with PTSD, 150; and desipramine, 93; and doxepin, 107; lorazepam for anxiety associated with, 103; and nortriptyline, 93; and trazodone, 106. *See also* atypical depression; major depressive disorder; manic depressive disorder; psychotic depression; treatment-resistant depression
- desipramine, 93
- desvenlafaxine, 79, 80, 82–3
- diabetes, 7
- diabetic peripheral neuropathic pain, and pregabalin, 101
- diagnosis, of PTSD, 26, 27. *See also* assessment; differential diagnosis; screening
- Diagnostic and Statistical Manual of Mental Disorders (DSM)*, 1, 25, 26
- dialectical behavior therapy (DBT), 135, 138, 147
- diazepam, 103
- dietary modifications, for patients on MAOIs, 96
- differential diagnosis, of PTSD and traumatic brain injury (TBI), 161
- dopamine: fluoxetine and release of, 70; and functioning in prefrontal cortex, 56–7; and monoamine oxidase enzymes, 95. *See also* dopamine reuptake inhibition; dopamine transporter gene
- dopamine reuptake inhibition (DRI), and sertraline, 68
- dopamine transporter gene, 34
- dorsal anterior cingulate cortex (dACC), and neuroimaging studies of PTSD, 35
- dorsolateral prefrontal cortex (DLPFC), and obsessions, 14

## dosages and dosage range for:

acamprosate, 123; alprazolam, 103; amitriptyline, 93; arpiprazole, 115; asenapine, 119; citalopram, 75; clonazepam, 103; desipramine, 93; desvenlafaxine, 83; diazepam, 103; doxepin, 107; duloxetine, 85; escitalopram, 77; eszopiclone, 110; fluoxetine, 71; fluvoxamine, 73; gabapentin, 101; iloperidone, 118; imipramine, 93; lamotrigine, 121; lorazepam, 103; milnacipran, 87; mirtazapine, 105; moclobemide, 99; naltrexone, 123; nortriptyline, 93; paliperidone, 117; paroxetine, 67; phenelzine, 99; prazosin, 110; pregabalin, 101; quetiapine, 114; risperidone, 112; selegiline, 99; sertraline, 69; topiramate, 121; trancypromine, 99; trazodone, 106; venlafaxine, 81; zaleplon, 110; ziprasidone, 116; zolpidem, 110

doxepin, 107

drug interactions: and duloxetine, 84; and escitalopram, 76; and fluvoxamine, 72; and MAOIs, 97; and traumatic brain injury in PTSD patients, 167

duloxetine, 79, 84–5

early life stress, as risk factor for PTSD, 31

education, on mental illness in military, 159

emotions: and cognitive restructuring, 134; and fear, 5, 10; PTSD and emotional numbing, 27; and symptoms of persistent postconcussive syndrome, 163

endocrine system, and neurobiology of fear, 7

escitalopram, 65, 76–7

eszopiclone, 109, 110

excitatory amino acid transporter (EAAT), 53

exercise, and chronic pain, 153

exposure therapy: applications and

techniques of, 133; and chronic pain, 153; and conditioned fear extinction, 58; and dialectical behavior therapy, 138; as first-line therapy for PTSD, 132, 147

extended-release formulation, of venlafaxine, 80

eye movement desensitization and reprocessing (EMDR), 135, 137, 147

family psychiatric history, as risk factor for PTSD, 30

fear: amygdala and neurophysiology of, 3, 5, 6–7, 9, 10, 12; as core symptom of anxiety disorders, 2; and hippocampus, 11; and locus coeruleus, 46; neuroanatomy of compared to anxiety, 4; and neurotransmitters, 40. *See also* fear conditioning; fear extinction

fear conditioning: amygdala and stress response, 12; and beta blockers, 125; and catechol-O-methyl-transferase, 58; and D-cycloserine, 127; and SERT genotype, 43

fear extinction, 127

fibromyalgia, and pregabalin, 101

fight/flight reaction, 6

FKBP5 gene, 34

fluoxetine, 65, 70–1

fluvoxamine, 65, 72–3

Freud, Sigmund, 24

functional brain scanning, and stress diathesis model, 20

GABA (gamma-aminobutyric acid): and

amygdala-centered neurocircuits, 40; and anticonvulsants, 120; and benzodiazepines, 102; key role of in experience and expression of anxiety, 50; potential targets for modulating, 51.

*See also* GABA transaminase; GABA transporter

Cambridge University Press

978-0-521-15399-7 - Stahl's Illustrated: Anxiety, Stress, and PTSD

Stephen M. Stahl and Meghan M. Grady and Nancy Muntner

Index

[More information](#)

- GABA-A receptors, 51, 102  
 GABA-B receptors, 51  
 gabapentin, 101, 153  
 GABA transaminase (GABA-T), 51  
 GABA transporter (GAT), 51  
 ganaxolone, 129  
 gender, and trauma types resulting in PTSD, 36, 37  
 generalized anxiety disorder: and  
   alprazolam, 103; and duloxetine, 84;  
   and escitalopram, 76  
 genetics: and risk factors for PTSD, 30, 34;  
   and serotonin transporter gene, 42–3;  
   and stress diathesis hypothesis, 19–22  
 Glasgow Coma Scale (GCS), 161, 164  
 glucocorticoid receptor antagonists, 128  
 glucocorticoids, 7, 8  
 glutamate, 40, 52–3  
 glycine, 53  
 gross stress reaction, 25  
 Gulf war, 160
- headaches, and PTSD, 146  
 heart rate (HR), 6  
 hepatic impairment. *See* special populations  
 hippocampal atrophy: and chronic stress, 8,  
   33; and PTSD, 30–3, 35, 63  
 hippocampus: and beta blockers, 125; fear  
   and fear conditioning, 11, 125; and  
   inhibition of stress response, 8; and  
   neuroimaging findings in PTSD, 35; small  
   size of as risk factor in PTSD, 30.  
   *See also* hippocampal atrophy  
 histamine 1 receptors, 92, 106  
 hydrocortisone, 124, 126  
 hyperarousal: and diagnostic criteria for  
   PTSD, 26, 27; and exposure therapy,  
   133. *See also* arousal  
 hypertension: MAOIs and crisis of, 96; and  
   prazosin, 110. *See also* blood pressure  
 hypnotics, and sedation, 109  
 hypocortisolism, 30
- hypothalamic pituitary adrenal (HPA) axis:  
   early life stress and dysregulation of, 31;  
   and physiology of fear, 7; and PTSD, 31,  
   55, 128; and stress responses, 8, 54
- iloperidone, 118  
 imaginal exposure, 133  
 imipramine, 93  
 impulse control, and suicide risk in  
   PTSD, 29  
 infants, and exposure to stress, 18  
 information processing: and stress diathesis  
   model, 20; and stress sensitized circuits,  
   17  
 insomnia: comorbidity of with PTSD, 152;  
   and eszopiclone, 110; and tricyclic  
   antidepressants, 92; and zaleplon, 110;  
   and zolpidem, 110. *See also* sleep  
   disturbances  
 interoceptive exposure, 133  
 investigational medications, 124  
 in vivo exposure, 133  
 Iraq war, 157–8, 160  
 irritability, and symptoms of PTSD, 27  
 irritable bowel syndrome, 146
- kainate, 53
- lamotrigine, 104, 120, 121, 148  
 locus coeruleus (LC): and noradrenergic  
   projections, 46; and physiology of fear, 6  
 lorazepam, 103
- magnetic resonance imaging (MRI), and  
   traumatic brain injury, 161  
 MAOIs. *See* monoamine oxidase inhibitors  
 major depressive disorder: comorbidity of  
   with PTSD, 28; and mirtazapine, 105;  
   and neurophysiological alterations from  
   early life stress, 31; and nortriptyline, 93;  
   and selegiline, 99; and tranylcypromine,  
   99. *See also* depression

- mania: and aripiprazole, 115; and olanzapine, 113; and quetiapine, 114; and ziprasidone, 116. *See also* bipolar disorder
- manic depressive disorder, and doxepin, 107
- mental health professionals, limited access to in military, 159
- metabotropic glutamate receptors (mGluR), 53
- methadone, 149
- met/met genotype, 57, 58
- military population: barriers to mental health care for, 159; impact of Iraq and Afghanistan wars on mental health of, 157; increase in prevalence of PTSD in, 155; and persistent postconcussive syndrome, 163–8; physical symptoms as common presentation of PTSD in, 160; and risk factors for PTSD, 156; and traumatic brain injury, 161–3. *See also* combat; warfare
- milnacipran, 79, 86–7
- mindfulness, and dialectical behavior therapy, 138
- mirtazapine, 104, 105, 148
- moclobemide, 99
- modafinil, 168
- monoamine oxidase (MAO) enzymes: and dopamine, 95; and norepinephrine, 48, 95; and serotonin, 44, 95; and tyramine reactions to MAOIs, 98
- monoamine oxidase inhibitors (MAOIs): clinical characteristics of, 99; and drug interactions, 97; mechanism of action, 94–5; and tyramine reactions, 96, 98
- motivational interviewing, 140, 142, 147, 149
- muscarinic M1 receptor blockade, and tricyclic antidepressants, 92
- naltrexone, 104, 122–3, 148, 149
- natural disasters, and risk of PTSD, 36, 37
- neuroactive steroids, 129
- neurobiology: of fear and worry, 2–14; and neurocircuits in anxiety disorders, 15–22. *See also* amygdala; hippocampus; hypothalamic pituitary adrenal (HPA) axis; locus coeruleus; neurotransmitters; prefrontal cortex
- neuroimaging studies, of PTSD, 35
- neurotransmitters: of fear and worry, 40; and GABA pathways, 50–1; and glutamate pathways, 52–3; and noradrenergic pathways, 46–9; and serotonergic pathways, 41–5; and voltage-sensitive ion channels, 54. *See also* dopamine; GABA; norepinephrine; serotonin
- nicotine dependence, 149
- nightmares: and alpha 1 antagonists, 108, 152; and symptoms of PTSD, 27; and trazodone, 106
- nitric oxide synthetase (NOS) inhibitors, 66
- NMDA (N-methyl-D-aspartate), 53
- noradrenergic pathways. *See* norepinephrine
- norepinephrine: and circuits of fear and worry, 40; and monoamine oxidase enzymes, 95; and potential mechanisms for novel anxiolytics, 47; potential targets for modulating neurotransmission of, 48–9; and prefrontal cortex, 56
- norepinephrine reuptake inhibition (NRI): and desvenlafaxine, 82; and duloxetine, 84; and fluoxetine, 70; and milnacipran, 86; and paroxetine, 66; and serotonin norepinephrine reuptake inhibitors, 78; and venlafaxine, 80
- norepinephrine transporter (NET), 48, 91
- nortriptyline, 93
- obsessions, and worry, 14
- obsessive-compulsive disorder, and fluvoxamine, 72

- olanzapine, 113
- opiate dependence, and PTSD, 149, 153
- opioids, and MAOIs, 97
- orbitofrontal cortex (OFC), and emotional aspects of fear, 5
- pain. *See* chronic pain
- paliperidone, 117
- panic attacks, symptoms of, 9
- panic disorder: and alprazolam, 103; and clonazepam, 103
- parabrachial nucleus (PBN), and fear response, 9
- paroxetine, 65, 66–7, 148
- periaqueductal grey (PAG), and fear response, 10
- persistent postconcussive syndrome (PPCS), 163–6, 168
- pharmacological treatments, for PTSD:
  - overview of adjunct medications, 104;
  - overview of first-line medications, 59–60;
  - overview of investigational medications, 124; overview of second-line medications, 89–90. *See also* alpha 2 delta ligands; anticonvulsants; antidepressants; antipsychotics; benzodiazepines; dosages and dosage range; drug interactions; monoamine oxidase inhibitors; selective serotonin reuptake inhibitors; serotonin norepinephrine reuptake inhibitors; side effects; special populations; stimulants; *specific medications*
- phenelzine, 99
- physical attack, and risk of PTSD, 36
- physical illnesses, as comorbid with PTSD, 146
- physical symptoms, and presentation of PTSD in veterans, 160
- postherpetic neuralgia, and alpha 2 delta ligands, 101
- postsynaptic GABA receptor, 51
- postsynaptic glutamate receptor, 53
- postsynaptic norepinephrine receptor, 49
- postsynaptic serotonin receptors, 45
- Posttraumatic Diagnostic Scale (PDS), 144
- posttraumatic stress disorder (PTSD):
  - acceptance and commitment therapy for, 139; adjunct medications for, 104, 148; and alcohol abuse, 122; and anticonvulsants, 120; and anxiety disorders, 28, 151; assessment tools for, 144; beta blockers and prevention of, 125; and chronic pain, 28, 38, 153, 160; clinical picture of, 27; and cognitive restructuring, 134; common comorbidities in, 28, 122; criteria controversies and future of, 26; and depression, 150; diagnostic criteria for, 26; and dialectical behavior therapy, 138; and duloxetine, 84; and early life stress, 31; and escitalopram, 76; exposure therapy for, 133; and eye movement desensitization and reprocessing, 137; and genetics, 34; and hippocampal volume, 30, 31, 32, 33, 35, 63; historical perspective on, 24–5; and HPA axis, 32, 55, 128; hydrocortisone and prevention of, 126; and hyperarousal, 26, 27, 133; investigational medications for, 124; and military population, 155–68; and monoamine oxidase inhibitors, 99; and motivational interviewing, 142; and neuroactive steroids, 129; neuroimaging findings in, 35; and noradrenergic hyperactivation, 47; overview of cognitive behavioral therapy for, 131–2, 135, 140, 147; overview of first-line medications for, 59–60, 148; overview of second-line medications for, 89–90, 148; and persistent postconcussive syndrome (PPCS), 168; and prazosin, 108; prevalence of, 23, 36, 155; and quetiapine, 114; and reexperiencing symptoms, 11, 26, 27, 133; risk factors

- for, 30–1, 33, 34; and risperidone, 112; and serotonin, 41; and serotonin norepinephrine reuptake inhibitors, 78; sleep disturbances and nightmares in, 108, 109, 152; and stress inoculation training, 136; and substance abuse, 149; and suicide risk, 29; and types of trauma, 36–7; and venlafaxine, 80
- Posttraumatic Stress Disorder Checklist (PCL), 144
- prazosin, 108, 110
- prefrontal cortex (PFC): COMT genotype and activation of, 57; and dopamine, 56–7; and glutamate pathways, 52; and noradrenergic projections, 46
- pregabalin, 101, 153
- pregnancy. *See* infants; special populations
- pregnanolone, 129
- presymptomatic states, and anxiety disorders, 16
- presynaptic norepinephrine receptor, 49
- presynaptic serotonin receptor (5HT1B/D), 45
- prevalence: of mental health issues in military population, 157; of PTSD, 23, 36, 155
- prevention, of PTSD by administration of medications after exposure to trauma, 125–6
- Primary Care Posttraumatic Stress Disorder Screen (PC-PTSD), 144
- prodromal symptoms, 17
- psychiatric history, and risk of suicide in PTSD, 145
- psychosocial situation, and risk of suicide in PTSD, 145
- psychotic depression: and doxepin, 107; and sertraline, 68
- PTSD. *See* posttraumatic stress disorder
- quetiapine, 114
- rape, and risk of PTSD, 36, 37
- reexperiencing: and diagnostic criteria for PTSD, 26, 27; and exposure therapy, 133; and hippocampus, 11; and relationship between PTSD and chronic pain, 38
- renal impairment. *See* special populations
- R enantiomer, of citalopram, 74, 76
- respiration rate, and fear response, 9
- reversible inhibition of MAO-A (RIMA), 98
- risk factors: and prediction of PTSD, 30, 31, 33, 34; for PTSD in military population, 156, 158; for suicide in PTSD, 29, 145
- risperidone, 112
- rostral anterior cingulate cortex (rACC), 35
- safety. *See* side effects; suicide and suicidal ideation
- schizophrenia, and atypical antipsychotics, 111–19
- screening: and assessment tools for PTSD, 144; for risk of suicide in PTSD, 145
- sedation: and antidepressants, 105–7; and hypnotics, 109
- seeking safety therapy, 140, 141, 147, 149
- seizures and seizure disorders: and anticonvulsants, 121; and clonazepam, 103; and gabapentin, 101; and pregabalin, 101
- selective serotonin reuptake inhibitors (SSRIs): as first-line medications for PTSD, 60, 148; mechanisms of action, 61–3; secondary pharmacological properties of, 64; and specific agents, 65
- selegiline, 98, 99
- S enantiomer, of citalopram, 74
- serotonin: fear and worry circuits, 40; and monoamine oxidase enzymes, 95; potential pharmacological targets for modulating, 44–5; and PTSD, 41. *See also* serotonin receptors; serotonin reuptake inhibition; serotonin syndrome; serotonin transporter

- serotonin norepinephrine reuptake inhibitors (SNRIs): and chronic pain, 153; as first-line medications for PTSD, 60, 148; mechanisms of action, 78; and specific agents, 79
- serotonin (5HT<sub>2C</sub>) receptors, and fluoxetine, 70
- serotonin reuptake inhibition (SRI): and desvenlafaxine, 82; and duloxetine, 84; and escitalopram, 76; and fluoxetine, 70; and milnacipran, 86; and paroxetine, 66; and serotonin norepinephrine reuptake inhibitors, 78; and venlafaxine, 80. *See also* selective serotonin reuptake inhibitors (SSRIs)
- serotonin syndrome, and MAOIs, 97
- serotonin transporter (SERT): and citalopram, 74; and genetic risk factors for PTSD, 34; and genetics of amygdala response to fearful stimuli, 42–3; and mechanism of action of SSRIs, 61; and modulation of serotonergic neurotransmission, 44–5; and tricyclic antidepressants, 91
- sertraline, 65, 68–9, 148
- shell shock, 24
- side effects: of citalopram, 75; of desvenlafaxine, 83; of duloxetine, 85; of escitalopram, 77; of fluoxetine, 71; of fluvoxamine, 73; of milnacipran, 87; of olanzapine, 113; of paroxetine, 67; of quetiapine, 114; of risperidone, 112; of sertraline, 69; of tricyclic antidepressants, 92; of venlafaxine, 81
- sigma 1 receptors, 68, 72
- SLC6A3 9 repeat allele, 34
- sleep disturbances: and alpha 1 antagonists, 108; and diagnosis of PTSD, 27; and risperidone, 112; and sedative hypnotics, 109; treatment of PTSD and comorbid, 152. *See also* insomnia; nightmares
- smoking cessation, 149
- social support, and risk factors for PTSD, 30
- sodium, and voltage-sensitive ion channels, 54
- SPAN, 144
- special populations: and citalopram, 75; and desvenlafaxine, 83; and duloxetine, 85; and escitalopram, 77; and fluoxetine, 71; and fluvoxamine, 73; and milnacipran, 87; and paroxetine, 67; and sertraline, 69; and venlafaxine, 81. *See also* infants; military population
- startle responses, and diagnosis of PTSD, 27
- stigma, as barrier to mental health care in military, 159
- stimulants: and MAOIs, 97; and PTSD patients with postconcussive symptoms, 168
- stress: exposure to in infancy, 18; and hippocampal volume, 33; and HPA activation, 7, 8; and neurobiology of sensitization to, 16–18; as risk factor for PTSD, 30, 31
- stress diathesis model, 19–22
- Stressful Life Events Screening Questionnaire (SLESQ), 144
- stress inoculation training (SIT), 135, 136, 147
- stroke, 7
- substance abuse: comorbidity of with PTSD, 28, 149; and military populations, 156; and risk of suicide in PTSD, 29; and seeking safety therapy, 141. *See also* alcohol abuse
- subsyndromal symptoms, 17
- suicide and suicidal ideation: and military populations, 156, 157; risk of in PTSD patients, 29, 145
- support groups, and comorbid PTSD and substance abuse, 149
- temporomandibular joint disorders (TMJ), 160
- threat with weapon, and risk of PTSD, 36, 37

Cambridge University Press

978-0-521-15399-7 - Stahl's Illustrated: Anxiety, Stress, and PTSD

Stephen M. Stahl and Meghan M. Grady and Nancy Muntner

Index

[More information](#)

- topiramate, 104, 120, 121, 148
- transdermal administration, of selegiline, 98
- transient situational personality disturbances, 25
- tranylcypromine, 99
- trauma: definition of, 23; and diagnostic criteria for PTSD, 26; relationship between type of and PTSD, 36–7
- traumatic brain injury (TBI), 155, 161–3, 167
- Trauma Questionnaire (TQ), 144
- trazodone, 106
- treatment-resistant depression: and olanzapine, 113; and quetiapine, 114
- tricyclic antidepressants (TCAs): and chronic pain, 153; clinical characteristics of select forms of, 93; mechanism of action, 91; side effects of, 92. *See also* antidepressants
- tyramine, and MAOIs, 96, 98
- val genotype, 57, 58
- Val66Met (BDNF gene), 34
- varenicline, 149
- vasopressin 1B receptors, 128
- venlafaxine, 78, 79, 80–1
- ventromedial prefrontal cortex (VMPC), and fear conditioning, 12, 125
- veterans. *See* combat; military population; warfare
- Vietnam War, 25
- voltage-sensitive ion channels, 40, 54, 100
- warfare, and historical perspective on PTSD, 24. *See also* combat; military population
- warning signs, of suicide in PTSD, 145
- withdrawal symptoms: and fluoxetine, 70; and paroxetine, 66; and venlafaxine, 80. *See also* alcohol abuse
- World War I and World War II, 24
- worry and worry loop, 2, 13, 14, 40
- zaleplon, 109, 110
- ziprasidone, 116
- zolpidem, 109, 110
- zopiclone, 109